1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 9,100 | 9,200 | 23:00 | |
| 9,000 | 9,400 | 22:00 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 04.02. | MiNK Therapeutics Presents New Data of allo-iNKT Cell Therapy as a Potential Disease-Modifying Approach in Idiopathic Pulmonary Fibrosis at Keystone Symposia | 1 | GlobeNewswire (USA) | ||
| 08.01. | MiNK Therapeutics and University of Wisconsin-Madison Announce Phase 1 Clinical Trial of Allo-iNKT Cell Therapy (AgenT-797) to Evaluate Prevention of Graft-Versus-Host Disease | 301 | GlobeNewswire (Europe) | Non-dilutive public-private funded trial with NIAID STTR & Mary Gooze Clinical Trial and Translation AwardExpands iNKT platform into transplantation with an off-the-shelf, HLA-independent, lymphodepletion-free... ► Artikel lesen | |
| 02.01. | MiNK Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 08.12.25 | MiNK Therapeutics, Inc. - 8-K, Current Report | 7 | SEC Filings | ||
| 20.11.25 | MiNK Therapeutics Announces New Data Showing MiNK-215 Drives Potent Anti-Tumor Activity in Treatment-resistant Solid Tumors | 1 | GlobeNewswire (USA) | ||
| 14.11.25 | MiNK Therapeutics Reports Q3 2025 Results and Accelerates iNKT Platform Toward Pivotal Development Across Oncology, Pulmonary Disease, and Transplantation | 245 | GlobeNewswire (Europe) | New clinical data show durable remissions and long-tail survivors including >2-year complete remissions in chemotherapy- and checkpoint-refractory cancersGVHD trial launching through non-dilutive... ► Artikel lesen | |
| 14.11.25 | MiNK Therapeutics GAAP EPS of -$0.65 beats by $0.20 | 2 | Seeking Alpha | ||
| 07.11.25 | MiNK Therapeutics Reports Durable Responses and Immune Reactivation with Allo-iNKT Cell Therapy agenT-797 in PD-1-Refractory Solid Tumors at SITC 2025 | 248 | GlobeNewswire (Europe) | Durable survival and deep, lasting remissions in checkpoint-refractory, heavily pretreated cancers with median OS of ~23 months with agenT-797 plus anti-PD-1Evidence of immune activation and tumor-immune... ► Artikel lesen | |
| MINK THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 05.11.25 | MiNK Therapeutics to Report Third Quarter 2025 Financial Results and Highlight Clinical and Corporate Milestones Advancing iNKT Platform Toward Pivotal Development | 3 | GlobeNewswire (USA) | ||
| 30.10.25 | MiNK Therapeutics to Present Late-Breaking Data on AgenT-797 in Solid Tumors at the 40th Annual Society for Immunotherapy of Cancer (SITC) Meeting | 3 | GlobeNewswire (USA) | ||
| 29.09.25 | MiNK Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 29.09.25 | MiNK Therapeutics appoints trauma expert Dr. John Holcomb to board | 2 | Investing.com | ||
| 29.09.25 | MiNK Therapeutics Appoints Colonel (Ret.) John B. Holcomb, MD, to Board of Directors | 11 | GlobeNewswire (USA) | ||
| 25.09.25 | MiNK Therapeutics Dr. Jennifer Buell to Deliver Featured Plenary at 10th Annual CAR-TCR Summit in Boston, MA | 2 | GlobeNewswire (USA) | ||
| 18.09.25 | MiNK Therapeutics Appoints Dr. Terese C. Hammond to Accelerate iNKT Pipeline to Pivotal Development | 1 | GlobeNewswire (USA) | ||
| 14.08.25 | MiNK Therapeutics Reports Clinical and Strategic Milestones and Second Quarter 2025 Results | 256 | GlobeNewswire (Europe) | Cash runway extended to deliver clinical program in GVHD and Ph2 results in 2L Gastric CancerDepartment of Defense STTR Grant to advance INKTs in GVHD announced; program advancingNew clinical grant... ► Artikel lesen | |
| 14.07.25 | XFRA 6Q40: WIEDERAUFNAHME/RESUMPTION | 384 | Xetra Newsboard | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| 11.07.25 | MiNK Therapeutics Announces Publication of Complete Remission Following Allogeneic iNKT Cell Therapy in Metastatic Testicular Cancer | 197 | GlobeNewswire (Europe) | NEW YORK, July 11, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic, off-the-shelf invariant natural killer T (iNKT)... ► Artikel lesen | |
| 02.06.25 | MiNK Therapeutics Awarded Prestigious NIAID Grant to Advance Allo-iNKT Cell Therapy for Prevention of GvHD in Stem Cell Transplant Patients | 107 | GlobeNewswire (Europe) | NEW YORK, June 02, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic, off-the-shelf invariant natural killer T (iNKT)... ► Artikel lesen | |
| 15.05.25 | MiNK Therapeutics Reports Q1 2025 Results and Highlights Clinical & Strategic Progress | 492 | GlobeNewswire (Europe) | Clinical data builds with CR in testicular cancer, enrollment in Phase 2 gastric trial, and new data in PD-1-resistant tumors Near-term capital transactions poised to bolster liquidity NEW YORK... ► Artikel lesen |
1 2 Weiter >>
21 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BB BIOTECH | 50,20 | -2,71 % | BB Biotech: Von Innovation zu Wertrealisierung - Der Biotech-Markt in einer neuen Phase | Nach mehreren Jahren, die von erhöhten Kapitalkosten, Bewertungsdruck und ausgeprägter Risikoaversion geprägt waren, hat sich das Umfeld seit dem vergangenen Jahr spürbar stabilisiert. Finanzierungsbedingungen... ► Artikel lesen | |
| VIKING THERAPEUTICS | 27,780 | -2,58 % | Viking Therapeutics: The High-Stakes Weight Loss Contender | ||
| NOVOCURE | 10,960 | -5,15 % | NovoCure's Optune Lua Secures Japan Health Ministry's Reimbursement Approval For NSCLC Patients | WASHINGTON (dpa-AFX) - NovoCure Limited (NVCR), Monday announced that Japan's Ministry of Health, Labour and Welfare approved reimbursement for Optune Lua, authorized for use in adult patients... ► Artikel lesen | |
| OXFORD NANOPORE TECHNOLOGIES | 1,338 | -1,18 % | Oxford Nanopore CEO receives share awards under compensation plan | ||
| MEREO BIOPHARMA | 0,344 | +1,78 % | XFRA MAH0: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| BIOLINERX | 2,200 | +1,85 % | BioLineRx Ltd.: BioLineRx Reports Third Quarter 2025 Financial Results and Provides Corporate Update | - Establishes joint venture with Hemispherian AS to advance GLIX1, a first-in-class, oral, small molecule targeting DNA damage response in glioblastoma and other... ► Artikel lesen | |
| ASSERTIO | 11,770 | +0,94 % | Assertio Holdings, Inc. Announces 1-for-15 Reverse Stock Split | LAKE FOREST, Ill.--(BUSINESS WIRE)--Assertio Holdings, Inc. ("Assertio" or the "Company") (NASDAQ: ASRT) today announced that it filed a certificate of amendment to its certificate of incorporation... ► Artikel lesen | |
| REVOLUTION MEDICINES | 87,50 | +0,57 % | Revolution Medicines, Inc.: Revolution Medicines Reports Fourth Quarter and Full Year 2025 Financial Results and Update on Corporate Progress | On track for readout of RASolute 302, a Phase 3 trial of daraxonrasib in second line metastatic PDAC, in first half of 2026Continues to advance broad late-stage pipeline, with five ongoing Phase 3... ► Artikel lesen | |
| APPLIED THERAPEUTICS | 0,077 | 0,00 % | Cycle Pharmaceuticals Completes Acquisition of Applied Therapeutics | Cycle Group Holdings Limited ("Cycle") is delighted to announce it has completed the acquisition of NASDAQ-listed Applied Therapeutics, Inc. (NASDAQ: APLT; "Applied"), a clinical-stage biopharmaceutical... ► Artikel lesen | |
| ROIVANT SCIENCES | 23,920 | -0,42 % | Roivant Sciences: Roivant Announces Genevant Sciences' and Arbutus Biopharma's $2.25 Billion Global Settlement With Moderna | ||
| ARVINAS | 12,980 | -2,99 % | Arvinas, Inc. (ARVN) Makes Significant Progress on Oncology and Neurology Trials | ||
| JANUX THERAPEUTICS | 13,050 | -2,76 % | Truist cuts Janux Therapeutics stock price target on competition | ||
| WEREWOLF THERAPEUTICS | 0,583 | 0,00 % | Werewolf Therapeutics, Inc.: Werewolf Therapeutics Announces Plan to Explore Strategic Alternatives | WATERTOWN, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (Nasdaq: HOWL) (the "Company" or "Werewolf"), an innovative biopharmaceutical company pioneering the development of... ► Artikel lesen | |
| TRANSCODE THERAPEUTICS | 9,990 | 0,00 % | Transcode Therapeutics, Inc. - 8-K, Current Report | ||
| SILEXION THERAPEUTICS | 1,740 | 0,00 % | Silexion Therapeutics Corp: Silexion Therapeutics Releases CEO Letter to Shareholders Highlighting 2025's Significant Achievements and Outlining Upcoming Milestones for 2026 | SIL204 Demonstrated Significant Tumor Inhibition in Positive Pre Clinical Studies with Activity Across Pancreatic, Colorectal, and Lung Cancer Models Company's Platform Seeks to Address an Estimated... ► Artikel lesen |
Das Unternehmen MINK THERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 8,350 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu MINK THERAPEUTICS INC finden Sie auf Wallstreet Online.